GlobeNewswire Inc.··Greenwich Lifesciences, Inc.Greenwich LifeSciences Accelerates FLAMINGO-01 Trial With 33% Patient Screening Surge
Greenwich LifeSciences boosts FLAMINGO-01 screening by 33% to 800 patients yearly, with non-HLA-A*02 arm fully enrolled and showing 80% recurrence reduction.
GLSIbreast cancerGLSI-100